New Congress Brings Heightened Risk of Investigations for Life Sciences Companies

19 November 2018
View Debevoise Update
Key takeaways:
  • Pharmaceutical, biotech, and medical device companies may face a slate of new requests, hearings, and investigations by Democrat leadership in the House.
  • The anticipated leaders of the House Energy and Commerce Committee, the House Ways and Means Committee, and the House Committee on Oversight and Government Reform have expressed interest in issues including the pricing of prescription drugs, competition in the pharmaceutical industry, and drug safety.
  • When responding to inquiries from Congress, companies and executives should seek expert advice about the unique legal complications and public relations challenges that tend to accompany Congressional investigations.